Frequently Asked Questions on Middle East Respiratory Syndrome Coronavirus (MERS‐CoV) (WHO, May 17 2014)

[Giuseppe]

[Source: World Health Organization, full page: (LINK).]


Frequently Asked Questions on Middle East Respiratory Syndrome Coronavirus (MERS‐CoV)

9 May 2014

• What is Middle East respiratory syndrome (MERS)?
  • Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a novel coronavirus (MERS‐CoV) that was first identified in Saudi Arabia in 2012. Coronaviruses are a large family of viruses that can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).
  
  
• Where is MERS occurring?
  • The following countries have reported cases of MERS:
    • Jordan,
    • Kuwait,
    • Oman,
    • Qatar,
    • Saudi Arabia,
    • the United Arab Emirates, and
    • Yemen (Middle East);
    • France,
    • Germany,
    • Greece,
    • Italy, and
    • the United Kingdom (UK) (Europe);
    • Tunisia and
    • Egypt (Africa);
    • Malaysia and
    • the Philippines (Asia); and
    • the United States of America (Americas).
    
    
  • The virus appears to be circulating widely throughout the Arabian Peninsula. All recent cases that have been reported outside the Middle East first developed infection in the Middle East; then the cases were exported outside the region.
  • These travel‐related cases do not appear to have infected others in their countries. In 2013 cases exported to France and the UK led to limited human‐to‐human transmission.
  • The latest information on cases can be found in WHO Disease Outbreak News at http://www.who.int/csr/don/en/.
  
  
• What are the symptoms of MERS?
  • A typical case of MERS consists of fever, cough, and shortness of breath. Pneumonia is a common finding on examination. Gastrointestinal symptoms, including diarrhoea, have also been reported. Severe illness can cause respiratory failure that requires mechanical ventilation and support in an intensive‐care unit. Some patients have had organ failure, especially of the kidneys, or septic shock. Approximately 27% of patients with MERS have died. The virus appears to cause more severe disease in people with weakened immune systems, older people, and those with such chronic diseases as diabetes, cancer, and chronic lung disease.
  
  
• Can a person be infected with the MERS virus and not be ill?
  • Yes. In some people, infection has not appeared to have caused symptoms. Such persons have been found because they were tested for MERS‐CoV during follow‐up studies of contacts of people with MERS infection.
  
  
• How do people get MERS?
  • It is not yet understood exactly how people become infected with MERS‐CoV. In some cases, the virus appears to pass from an infected person to another person in close contact. This has been seen among family members, patients, and health‐care workers. Recently, there have been an increased number of reports of health care‐associated infections. In some communities, people have become ill but no potential source of infection has been found. It is possible that these persons were infected by exposure to an animal or perhaps another source or person.
  
  
• Is MERS contagious?
  • Yes, but apparently only to a limited extent. The virus does not seem to pass easily from person to person unless there is close contact, such as occurs when providing unprotected care to a patient. There have been clusters of cases in health‐care facilities, where human‐to‐human transmission appears to be more efficient, especially when infection prevention and control practices are inadequate. Thus far, no sustained community transmission has been documented.
  
  
• What is the source of the MERS virus?bats, camels, domestic animals?
  • The full picture on the source is not yet clear. Strains of MERS‐CoV that match human strains have been isolated from camels in Egypt, Qatar, and Saudi Arabia. These and other studies have found MERS‐CoV antibodies in camels across Africa and the Middle East. Human and camel genetic sequence data demonstrate a close link between the virus found in camels and that found in people. It is possible that other reservoirs exist. However, other animals, including goats, cows, sheep, water buffalo, swine, and wild birds, have been tested for antibodies to MERS‐CoV, but so far none have been found in these animals. These studies combined support the premise that camels are a likely source of infection in humans.
  
  
• Should people avoid contact with camels or camel products? Is it safe to visit farms, markets, or camel fairs?
  • As a general precaution, anyone visiting farms, markets, barns, or other places where animals are present should practice general hygiene measures, including regular hand washing before and after touching animals, and avoid contact with sick animals.
  • The consumption of raw or undercooked animal products, including milk and meat, carries a high risk of infection from a variety of organisms that might cause disease in humans. Animal products processed appropriately through cooking or pasteurization are safe for consumption, but should also be handled with care to avoid cross‐contamination with uncooked foods. Camel meat and camel milk are nutritious products that can continue to be consumed after pasteurization, cooking, or other heat treatments.
  • Until more is understood about MERS, people with diabetes, renal failure, chronic lung disease, and immunocompromised persons are considered to be at high risk of severe disease from MERS‐CoV infection. Therefore, these people should avoid contact with camels, drinking raw camel milk or camel urine, or eating meat that has not been properly cooked.
  • Camel farm and slaughterhouse workers should practice good personal hygiene, including frequent hand washing after touching animals, facial protection where feasible, and the wearing of protective clothing, which should be removed after work and washed daily. Workers should also avoid exposing family members to soiled work clothing, shoes, or other items that may have come into contact with camels or camel excretions. Sick animals should never be slaughtered for consumption. People should avoid direct contact with any animal that has been confirmed positive for MERS‐CoV.
  
  
• Is there a vaccine against MERS‐CoV? What is the treatment?
  • No vaccine or specific treatment is currently available. Treatment is supportive and based on the patient?s clinical condition.
  
  
• Are health‐care workers at risk from MERS‐CoV?
  • Yes. Transmission has occurred in health‐care facilities in several countries, including from patients to health‐care providers. It is not always possible to identify patients with MERS‐CoV early or without testing because symptoms and other clinical features may be non‐specific. For this reason, it is important that health‐care workers apply standard precautions consistently with all patients. Droplet precautions should be added to standard precautions when providing care to all patients with symptoms of acute respiratory infection. Contact precautions and eye protection should be added when caring for suspected or confirmed cases of MERS‐CoV infection. Airborne precautions should be applied when performing aerosol‐generating procedures.
  
  
• Is it safe to travel to the Middle East? Does WHO recommend any travel or trade restrictions related to this new virus?
  • WHO does not recommend the application of any travel or trade restrictions or entry screening related to MERS‐CoV.
  
  
• How is WHO responding to the MERS outbreak?
  • WHO is working with clinicians and scientists to gather and share scientific evidence to better understand the virus and the disease it causes, and to determine outbreak response priorities, treatment strategies, and clinical management approaches. WHO is working with affected countries and international technical partners and networks to coordinate the global health response, including providing updated information on the situation, conducting risk assessments and joint investigations with national authorities, convening scientific meetings, and developing guidance and training for health authorities and technical health agencies on interim surveillance recommendations, laboratory testing of cases, infection prevention and control, and clinical management.
  • The Director‐General has convened an Emergency Committee under the International Health Regulations (2005) to advise her as to whether this event constitutes a Public Health Emergency of International Concern (PHEIC) and on public health measures that should be taken. This Committee will be reconvened as new developments require (http://who.int/ihr/ihr_ec_2013/en/ ).
  
  
• What is WHO recommending?
  • For countries
    • WHO encourages all Member States to enhance their surveillance for severe acute respiratory infections (SARI) and to carefully review any unusual patterns of SARI or pneumonia cases. WHO urges Member States to notify or verify to WHO any probable or confirmed case of infection with MERS‐CoV. WHO also encourages countries to raise awareness of MERS and to provide information to travellers as below.
      • Information on the identification and investigation of cases: http://www.who.int/csr/disease/coronavirus_infections/MERS_CoV_investigation_guideline_Jul13.pdf?
      • Procedures for handling laboratory samples:
        http://www.who.int/csr/disease/coronavirus_infections/MERS_Lab_recos_16_Sept_2013.pdf?ua=1
      • Guidelines for clinical management: http://who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCorona virus_11Feb13u.pdf?ua=1
    
    
  • For health‐care workers
    • Infection prevention and control measures are critical to prevent the possible spread of MERS‐CoV in health‐care facilities. Health‐care facilities that provide care for patients suspected or confirmed to be infected with MERS‐CoV infection should take appropriate measure to decrease the risk of transmission of the virus from an infected patient to other patients, health‐care workers, and visitors. Health‐care workers should be educated, trained, and refreshed with skills on infection prevention and control.
    • Guidelines for infection prevention and control:
      • http://www.who.int/csr/bioriskreduction/infection_control/publication/en/
      • http://who.int/csr/disease/coronavirus_infections/MERS_home_care.pdf?ua=1
    
    
  • Travel advice for countries, practitioners, and individuals
    • The following advice is given to reduce the risk of MERS‐CoV infection among travellers and those associated with their travel, including transport operators and ground staff, and to increase selfreporting of illness by travellers:
      • advise travellers to the Middle East that pre‐existing major medical conditions (e.g. chronic diseases such as diabetes, chronic lung disease, immunodeficiency) can increase the likelihood of illness, including MERS‐CoV infection, during travel;
      • make information known to departing travellers and travel organizations on general travel health precautions, which will lower the risk of infection in general, including illnesses such as influenza and traveller?s diarrhoea.
      • Specific emphasis should be placed on:
        • washing hands often with soap and water (when hands are not visibly dirty, a hand rub can be used);
        • adhering to good food‐safety practices, such as avoiding undercooked meat or food prepared under unsanitary conditions, and properly washing fruits and vegetables before eating them; and
        • maintaining good personal hygiene;
        
        
      • make health advisories available to all departing travellers to the Middle East by working with the travel and tourism sectors and placing such materials at strategic locations (e.g. travel agencies or points of departure in airports). Different kinds of communication, such as health alerts on board planes and ships, and banners, pamphlets, and radio announcements at international points of entry, can also be used to reach travellers. Travel advisories should include current information on MERS‐CoV and guidance on how to avoid illness while travelling.
      • advise travellers who develop a significant acute respiratory illness with fever and cough (severe enough to interfere with usual daily activities) to:
        • minimize their contact with others to keep from infecting them;
        • cover their mouth and nose with a tissue when coughing or sneezing, then discard the tissue in the trash after use and wash hands afterwards, or, if this is not possible, to cough or sneeze into the upper sleeves of their clothing, but not into their hands; and
        • report to medical staff as soon as possible.
        
        
      • advise returning travellers from the Middle East that if they develop a significant acute respiratory illness with fever and cough (severe enough to interfere with usual daily activities) during the two weeks after their return, they should seek medical attention and immediately notify their local health authority;
      • advise persons who have had close contact with a traveller with a significant acute respiratory illness with fever and cough (severe enough to interfere with usual daily activities) and who themselves develop such an illness to report to local health authorities to be monitored for MERS‐CoV;
      • alert practitioners and facilities to the possibility of MERS‐CoV infection in returning travellers from the Middle East with acute respiratory illness, especially those with fever and cough and pulmonary parenchymal disease (e.g. pneumonia or the acute respiratory distress syndrome). If clinical presentation suggests the diagnosis of MERS‐CoV, laboratory testing in accordance with WHO?s case definition should be done and infection prevention and control measures implemented. Clinicians should also be alerted to the possibility of atypical presentations in patients who are immunocompromised.
      
      
    • As required by the IHR, countries should ensure that routine measures are in place for assessing ill travellers detected on board conveyances (such as planes and ships) and at points of entry, as well as measures for safe transportation of symptomatic travellers to hospitals or designated facilities for clinical assessment and treatment. If a sick traveller is on board a plane, a passenger locator form can be used. This form is useful for collecting contact information for passengers, which can be used for followup if necessary.

-
-------